Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug131 | ARDSNet Wiki | 1.00 |
| drug1307 | EIT-Group Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.07 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The aim of the study is to demonstrate the feasibility and validity of a saliva based home surveillance monitoring test for SARS-CoV-2 infection. Participants will be asked to carry out as many tests as are included in the bag they are provided, on a daily basis until they are used up. Number of Tests Provided to Participants: 1. Five tests to each hospitalized patient 2. Two tests to each high risk or positive patient 3. Three tests to each participant from the low risk population
Description: Primary Feasibility Outcome
Measure: An indicator for discrepancy in interpretation of findings by participant versus by technician via photo (interrater reliability) Time: Up to 5 days per participantDescription: Primary Validity Outcome
Measure: An indicator for whether the home saliva test is positive as determined by the patient (to assess sensitivity and specificity by the patient) Time: Up to 5 days per participantDescription: Secondary Feasibility Outcome
Measure: An indicator for ambiguous findings as measured by percent confidence (if < 80% confident) in interpretation of results by participant and by technician (ease of interpretation) Time: Up to 5 days per participantDescription: Secondary Feasibility Outcome
Measure: An indicator that the participant appropriately followed instructions for using the kit (≥ 80% confident) (ease of use) Time: Up to 5 days per participantDescription: Secondary Feasibility Outcome
Measure: An indicator for whether participant called technical support and by reason (e.g., centrifuging was not possible due to broken part) (ease of use) Time: Up to 5 days per participantDescription: Secondary Feasibility Outcome
Measure: An indicator by participant that the sample was sufficient and reached the indicated line for sample integrity (sample integrity) Time: Up to 5 days per participantDescription: Secondary Validity Outcome
Measure: An indicator for whether the home saliva test is positive as determined by the technician (to assess sensitivity and specificity by the technician) Time: Up to 5 days per participantAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports